DFTX · XBRL financial data

Definium Therapeutics financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (DFTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Research and development	34,789	36,169	52,124	65,297	117,665
General and administrative	59,065	30,162	41,742	38,619	48,644
Total operating expenses	93,854	66,331	93,866	103,916	166,309
Operating income (loss)	(93,854)	(66,331)	(93,866)	(103,916)	(166,309)
Interest expense	—	—	920	2,283	5,482
Other income (expense)	(339)	9,535	(1,866)	(4,763)	(17,484)
Income tax expense (benefit)	(1,157)	—	—	—	0
Net income (loss)	(93,036)	(56,796)	(95,732)	(108,679)	(183,793)
Earnings per share, basic USD per share	(3.40)	(1.84)	(2.44)	(1.54)	(2.06)
Earnings per share, diluted USD per share	(3.40)	(1.84)	(2.44)	(1.54)	(2.06)
Weighted average shares, basic thousands of shares	27,377	30,857	39,157	70,461	89,328
Weighted average shares, diluted thousands of shares	27,377	30,857	39,157	70,461	89,328

† Share count changed about 1/11 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (DFTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	133,539	142,142	99,704	273,741	257,837
Short-term investments	—	—	—	0	153,756
Prepaid and other current assets	3,676	3,913	4,168	7,879	7,727
Total current assets	137,215	146,055	103,872	281,620	419,320
Goodwill	19,918	19,918	19,918	19,918	19,918
Total assets	164,002	169,993	124,541	302,151	440,100
Accounts payable	4,178	2,111	4,136	2,010	5,347
Accrued liabilities	6,230	5,877	11,634	12,829	20,446
Total current liabilities	10,408	17,892	32,246	38,849	66,698
Long-term debt	—	—	14,129	21,854	40,579
Total liabilities	12,338	19,076	46,407	60,703	107,773
Accumulated deficit	(137,672)	(194,468)	(290,200)	(398,879)	(582,672)
Total stockholders' equity	151,664	150,917	78,134	241,448	332,327
Total liabilities and equity	164,002	169,993	124,541	302,151	440,100
Common shares outstanding (cover page) thousands of shares	421,885	38,063	41,334	75,368	99,698

† Share count changed about 1/11 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (DFTX's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022†Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(93,036)	(56,796)	(95,732)	(108,679)	(183,793)
Net cash from operating activities	(45,824)	(50,139)	(64,365)	(79,129)	(131,560)
Net cash from investing activities	(297)	—	—	0	(151,606)
Proceeds from issuing common stock	81,924	42,297	7,529	984	0
Net cash from financing activities	98,824	59,051	21,848	253,196	267,269
Net change in cash	53,445	8,603	(42,438)	174,037	(15,904)

† Share count changed about 1/11 in the period ending 2022-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2833 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2833 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Definium Therapeutics	655,267	not reported	(52,778)*	134.4M	20.5 quarters	Q2 FY26 10-QJun 30, 2026
Myriad Genetics	115,200	190,700	(8,300)*	95.6M	13.9 quarters	Q2 FY26 10-QJun 30, 2026
Kura Oncology	70,242	20,874	(62,549)*	89.0M	8.3 quarters	Q2 FY26 10-QJun 30, 2026
KalVista Pharmaceuticals	213,768	40,863	(14,455)	53.2M	19.7 quarters	Q1 FY26 10-QMar 31, 2026
Arbutus Biopharma	19,171	1,014	(6,018)*	197.8M	15.4 quarters	Q2 FY26 10-QJun 30, 2026
Arvinas	88,000	500	(10,400)*	65.5M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
aTYR PHARMA	16,160	not reported	(9,351)*	98.1M	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Zevra Therapeutics	122,148	37,756	10,047*	59.5M	—	Q3 FY26 10-QSep 30, 2026
Theravance Biopharma	219,766	20,731	(6,965)*	51.9M	55.7 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.